A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
Latest Information Update: 08 May 2025
At a glance
- Drugs Paricalcitol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 12 Mar 2025 Planned End Date changed from 30 Oct 2026 to 1 Oct 2026.
- 12 Mar 2025 Planned primary completion date changed from 30 Jun 2026 to 1 Jun 2026.
- 24 Feb 2023 Planned primary completion date changed from 9 Mar 2024 to 30 Jun 2026.